ClinicalTrials.gg
Active, not recruitingNCT04328844Updated Jul 8, 2026

A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

A Phase 1 interventional study of IOA-244 and Avelumab Injection in Solid Tumor, Adult, Non-Hodgkin Lymphoma, Adult and NSCLC, sponsored by iOnctura. Active, not recruiting at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-08.

Sponsored by iOnctura · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
210
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 194 studies in Lymphoma, Non-Hodgkin with a site in Italy — 28 open to participants now, 51 under way, 11 of them phase 3. Lymphoma, Non-Hodgkin · Italy.

Planned enrollment
64th of 183
210 · median 133
Started
2020
with 3 others
Phase 1
40 of 194
5 open now
Primary completion
2023-12
later than 2 of 50 live
Registered
141st of 194
by date

Among the 194 studies in Lymphoma, Non-Hodgkin with a site in Italy, this one is the 64th largest by planned enrollment of the 183 interventional ones that give a count, is one of 4 that started in 2020, is one of 40 in phase 1, reaches primary completion later than 2 of the 50 other live ones, and was the 141st registered.

Lymphoma, Non-Hodgkin

2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

28 of the 194 studies in Lymphoma, Non-Hodgkin with a site in Italy are open now. Recruiting first, the newest first:

23 more — sign in →

All 28 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 194 studies in Lymphoma, Non-Hodgkin with a site in Italy, or all of them as a file.
02

Study summary

The objective of study IOA-244-101 is to determine whether IOA-244 is safe and tolerable in cancer patients (Part A). In addition, the study will assess whether IOA-244 can increase the anti-tumour immune response in patients both as monotherapy and in combination pemetrexed/cisplatin/avelumab (Part B Mesothelioma and NSCLC 1st line), in combination with avelumab (Part B Cutaneous Melanoma and NSCLC 2nd/3rd line) and ruxolitinib (Part B Primary Myelofibrosis)

03

Conditions studied

  • Solid Tumor, Adult
  • Non-Hodgkin Lymphoma, Adult
  • NSCLC
  • Myelofibrosis
  • Uveal Melanoma

Keywords

  • Mesothelioma
  • Melanoma
  • Follicular Lymphoma
  • NSCLC
  • Uveal Melanoma
  • Myelofibrosis
  • PTCL
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  1. ≥18 years of age inclusive, at the time of signing the .
  2. Capable of giving signed informed consent, which includes compliance with the requirements of this protocol.
  3. (ECOG) performance status of 0 to 1. For patients with NHL, ECOG 2 will be allowed.
  4. Patients with or cytologically confirmed advanced or (including histologically confirmed, unresectable Stage III or IV melanoma); see following details for each malignancy:

    For Patients with cutaneous and mucosal melanoma:

    1. Baseline lactate dehydrogenase levels are available.
    2. Disease progression is confirmed and they are eligible for second- or treatment:

      • After first-line treatment and progression on approved programmed cell death-1 () or cytotoxic T lymphocyte antigen-4 (CTLA-4) or combination of PD-1 and CTLA-4-pathway targeted agent.
      • After second-line treatment and progression on prior BRAF V600 mutation targeted agent followed by PD-1 or CTLA-4-pathway targeted agent (Note: There is no mandatory sequence of these approved treatments).
    3. No tumour-related symptoms.

    For Patients with metastatic ocular/uveal melanoma:

    Patients must have metastatic histologically or cytologically confirmed uveal melanoma.

    For Patients with advanced or metastatic mesothelioma:

    1. Histological confirmation of mesothelioma (any subtype).
    2. Part A: They received at least one prior line of treatment (including patients who were re-challenged with pemetrexed-based therapy). Prior maintenance therapy is permitted but will not count as a line of treatment.

    Part B: Considered for first-line treatment with pemetrexed/cisplatin and avelumab.

    For Patients with Indolent Non-Hodgkin Lymphoma, type Follicular Lymphoma (FL):

    1. Patients must have a past diagnosis of indolent Non-Hodgkin lymphoma, type Follicular Lymphoma, Grade 1-3A.(Dreyling et al., 2016)
    2. Patients must have been previously treated with at least 1 prior systemic chemotherapy, immunotherapy, or chemoimmunotherapy, such as rituximab monotherapy, chemotherapy given with or without rituximab, radioimmunoconjugates (e.g., 90Y-ibritumomab tiuxetan and 131I-tositumomab).
    3. Must have documented , refractory, or PD after treatment with systemic therapy (refractory defined as less than PR or disease progression \<6 months after last dose).
    4. Patients with prior exposure to a PI3K inhibitor (e.g., idelalisib/GS-1101, duvelisib) or a Bruton's tyrosine kinase (BTK) inhibitor are eligible if they discontinued either inhibitors in the last 4 weeks prior entering study treatment.
    5. Patients are not eligible for transplantation (autologous or any similar intervention, including CART-cell therapy).

    For Patients with Non-Hodgkin Lymphoma, type Peripheral T cell lymphoma (PTCL):

    1. Diagnosis of one of the following histologic subtypes of PTCL, pathologically-confirmed, as defined by the World Health Organization (other rare PTCL may be enrolled upon discussion with the medical monitor of this study):

      • Peripheral T-cell lymphoma - not otherwise specified (PTCL-NOS)
      • Angioimmunoblastic T-cell lymphomas (AITL)
      • Anaplastic large cell lymphoma (ALCL)
      • Natural-killer/T-cell lymphoma (NKTL)
    2. Received at least 2 cycles of one prior regimen administered with curative intent and one of the following:

      • failed to achieve at least a partial response after 2 or more cycles;
      • failed to achieve a complete response after 6 or more cycles; and/or
      • progressed after an initial response.
    3. For patients with CD30+ ALCL, failed or are ineligible or intolerant to brentuximab vedotin.
    4. as defined by IWG for PTCL, i.e., at least 1 measurable disease lesion > 1.5 cm in at least one dimension by 18FDG-PET-CT, MRI, or diagnostic CT.
    5. Patients with prior exposure to a PI3K inhibitor (e.g., idelalisib/GS-1101, duvelisib) or a Bruton's tyrosine kinase (BTK) inhibitor are eligible if they discontinued either inhibitors in the last 4 weeks prior entering study treatment.

    For Patients with Non-Small Cell Lung Cancer (NSCLC) 1st line:

    1. Histological diagnosis of locally advanced (primary or recurrent) NSCLC non-squamous not amenable for treatment with curative intent.
    2. No prior systemic treatment for unresectable locally advanced or metastatic disease for NSCLC.
    3. Non-squamous NSCLC, with no activating EGFR mutations, ALK or ROS1 translocations/rearrangements.
    4. If monotherapy pembrolizumab is available as a standard of care treatment option, patients must have a tumour proportion score (TPS) \<50% for PD-L1 (e.g., via the 22C3 pharmDx or the Ventana (SP263) PD-L1 IHC assay, or any other approved IHC assay.

    For Patients with Non-Small Cell Lung Cancer (NSCLC) 2nd or 3rd line:

    1. Histological confirmed Stage IIIb/IV or recurrent NSCLC who have experienced disease progression.
    2. Considered for 2nd line or 3rd line treatment either after radiographic progression or on stable disease:

      • Participants must have progressed after a minimum of 2 cycles of 1 course of a platinum based combination therapy administered for the treatment of a metastatic disease.

    For Patients with Primary Myelofibrosis (PMF):

    1. Diagnosis of PMF, Post-Polycythemia Vera Myelofibrosis MF(PPV-MF), or post-essential thrombocythemia MF (PET-MF)
    2. Dynamic International Prognostic Scoring System (DIPSS) risk category of intermediate-1, intermediate-2, or high.
    3. Treated with ruxolitinib for ≥ 3 months with a stable dose for at least the last 8 weeks prior to Day 1 and no significant spleen reduction (e.g., less than 15% spleen size reduction, or corresponding lack of response in spleen volume).
    4. Did not receive experimental drug therapy for MF or any other drug considered as an effective treatment for MF (eg, danazol, hydroxyurea, interferon products) within the last 2 months prior to starting study treatment.
    5. Splenic irradiation within 6 months before receiving the first dose of study drug.
    6. Independent of spleen size. active symptoms of MF at the screening visit, as demonstrated by the presence of a Total Symptom Score (TSS) of ≥ 10 using the Screening Symptom Form.
    7. Screening bone marrow specimen and pathology report(s) available that was obtained no more than 2 months prior to starting the study treatment or willingness to undergo a bone marrow biopsy at screening/baseline; willingness to undergo bone marrow biopsy at Week 24 and every 24 weeks thereafter. Screening/baseline biopsy specimen must show diagnosis of MF.
    8. Peripheral blast count \< 10%.
    9. Use of any potent inhibitors or inducers within 14 days or 5 half-lives (whichever is longer) before the first dose of study drug or anticipated during the study.
  5. Presence of measurable disease per v.1.1, or (for cohort with pleural mesothelioma patients), as determined by the site study team. Tumour lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.

    For NHL (FL and PTCL) patients: Have measurable disease as defined by the Lugano Classification, including at least one lymph node or tumour mass greater than or equal to 1.5 cm.

    For PMF patients: Have measurable disease as defined by IWG-MRT criteria.

  6. For patients with prior systemic therapies (Groups 1, 2, 6, and 7) disease progression must be reported after available therapies for advanced or metastatic disease that are known to confer clinical benefit, been intolerant to treatment, or refused standard treatment. Within 6 months and prior to entering the study, a patient who has completed an adjuvant, , or chemo-radiation regimens would be considered of having received 1 prior systemic regimen and would not require an additional systemic regimen for advanced or metastatic disease.
  7. Willingness to undergo a pre-treatment and on-treatment tumour biopsy to obtain the specimen (for NHL and PMF: see respective requirements).

    Note: If a patient has signed the informed consent and is scheduled to have a tumour biopsy for the purposes of this study, and it is subsequently determined that tumour tissue cannot safely be obtained, the patient may still enrol in the study, and the patient may be replaced, if enrolled in Part A, after discussion between the Sponsor and Investigator. The patient will be replaced if enrolled in Part B. However, all patients will be part of the final safety PK, PD (except for the examinations related to the pre- and post-dosing biopsy) and efficacy evaluation.

  8. Willingness to avoid pregnancy or fathering children based on the criteria below:

    1. Women of non- (i.e., surgically sterile with a hysterectomy and/or bilateral oophorectomy OR ≥ 12 months of amenorrhea and at least 50 years of age).
    2. Women of childbearing potential who had a negative serum pregnancy test at screening and who agree to take appropriate precautions to avoid pregnancy (with at least 99% certainty) from screening through safety follow-up, at least 1 month after the last dose of study treatment. Women receiving cisplatin should not become pregnant for at least 6 months after receiving the last dose of cisplatin. Permitted methods that are at least 99% effective in preventing pregnancy should be communicated to the patient and their understanding confirmed.
    3. Men who agree to take appropriate precautions to avoid fathering children (with at least 99% certainty) from screening through safety follow-up, at least 1 month after the last dose of study treatment. Men receiving pemetrexed and/or cisplatin should not father within 6 months of last treatment with pemetrexed and/or cisplatin. Permitted methods that are at least 99% effective in preventing pregnancy (see should be communicated to the patient and their understanding confirmed.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

iRECIST and mRECIST

Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
210 participants (estimated)

Study arms

  • Experimental
    Group 1: Cutaneous Melanoma

    IOA-244 in combination with avelumab

    Drug: IOA-244 · Drug: Avelumab Injection

  • Experimental
    Group 2: Uveal Melanoma

    IOA-244 as monotherapy

    Drug: IOA-244

  • Experimental
    Group 3: Myelofibrosis

    IOA-244 in combination with ruxolitinib

    Drug: IOA-244 · Drug: Ruxolitinib

  • Experimental
    Group 4: Mesothelioma

    IOA-244 in combination with pemetrexed/cisplatin/avelumab

    Drug: IOA-244 · Drug: Avelumab Injection · Drug: Pemetrexed · Drug: Cisplatin

  • Experimental
    Group 5: NSCLC 1st line

    IOA-244 in combination with pemetrexed/cisplatin/avelumab

    Drug: IOA-244 · Drug: Avelumab Injection · Drug: Pemetrexed · Drug: Cisplatin

  • Experimental
    Group 6: NSCLC 2nd/3rd line

    IOA-244 in combination with avelumab

    Drug: IOA-244 · Drug: Avelumab Injection

  • Experimental
    Group 7: NHL-FL and NHL-PTCL

    IOA-244 as monotherapy

    Drug: IOA-244

Interventions

  • IOA-244 will be administered orally once daily (QD)

  • Avelumab will be administered IV every 2 weeks

  • Pemetrexed will be administered IV every 3 weeks

  • Cisplatin will be administered IV every 3 weeks

  • Ruxolitinib will be administered orally twice a day (BD)

06

What researchers measure

Primary outcomes

  1. Numbers of participants with treatment-related adverse events as assessed by CTCAE v5.0

    Adverse Events will be assessed by nondirective questioning of the participants during the screening process, at each visit during the study and during the safety follow up period

    Time frame: From time of first drug administration to first documented progression, toxicity or death from any cause whichever occurs first, assessed at week 30

Secondary outcomes

  1. Cmax

    Peak Plasma Concentration

    Time frame: At Cycle 1 Day 1: 0 hours (pre-dose),1 hour, 2 hours, 3-4 hours and 6-8 hours post dose. From Cycle 2 Day 1 to Cycle 6 Day 1 (pre-dose). Each cycle is 28 days

  2. Cmin

    Minimum observed plasma concentration

    Time frame: At Cycle 1 Day 1: 0 hours (pre-dose),1 hour, 2 hours, 3-4 hours and 6-8 hours post dose. From Cycle 2 Day 1 to Cycle 6 Day 1 (pre-dose). Each cycle is 28 days

  3. t½

    Terminal elimination half-life

    Time frame: At Cycle 1 Day 1: 0 hours (pre-dose),1 hour, 2 hours, 3-4 hours and 6-8 hours post dose. From Cycle 2 Day 1 to Cycle 6 Day 1 (pre-dose). Each cycle is 28 days

  4. tmax

    Time of the maximum observed plasma concentration

    Time frame: At Cycle 1 Day 1: 0 hours (pre-dose),1 hour, 2 hours, 3-4 hours and 6-8 hours post dose. From Cycle 2 Day 1 to Cycle 6 Day 1 (pre-dose). Each cycle is 28 days

  5. AUC0-t

    Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration

    Time frame: At Cycle 1 Day 1: 0 hours (pre-dose),1 hour, 2 hours, 3-4 hours and 6-8 hours post dose. From Cycle 2 Day 1 to Cycle 6 Day 1 (pre-dose). Each cycle is 28 days

  6. AUC0-∞

    Area under the plasma concentration-time curve from time zero extrapolated to infinity

    Time frame: At Cycle 1 Day 1: 0 hours (pre-dose),1 hour, 2 hours, 3-4 hours and 6-8 hours post dose. From Cycle 2 Day 1 to Cycle 6 Day 1 (pre-dose). Each cycle is 28 days

  7. Pharmacodynamic activity of IOA-244 by determining changes in Lymphocytes counts

    Lymphocytes Immunophenotyping in peripheral blood

    Time frame: At Cycle 1 Day 1, Day 2, Day 15 (pre-dose), From Cycle 2 to Cycle 6 Day 1 (pre-dose). Each cycle is 28 days

  8. Pharmacodynamic activity of IOA-244 by determining changes in LDH

    Levels of Lactate Dehydrogenase (LDH)

    Time frame: At Screening (D-28 to D-1), Cycle 1 Day 1, Day 8, Day 15, Day 22 (pre-dose). Each cycle is 28 days

  9. Pharmacodynamic activity of IOA-244 by evaluating levels of Mesothelin

    Levels of Mesothelin (Mesothelioma participants only)

    Time frame: At Cycle 1, Day 1 and Day 15 (pre-dose) , From Cycle 2 to Cycle 6, Day 1 (pre-dose). Each cycle is 28 days

  10. Objective Response Rate (ORR)

    Percentage of participants with a Complete Response (CR) or Partial Response (PR) RECIST 1.1, for participants with Mesothelioma, modified RECIST and the Lugano 2014 criteria for NHL participants

    Time frame: Up to 28 weeks

  11. Duration of response (DOR)

    DOR among patients who achieve objective response as determined by radiographic disease assessment

    Time frame: From date of the first documented evidence of CR or PR until the date of first documented disease progression or date of death from any cause, whichever came first, assessed up to 54 weeks

  12. Progression Free Survival (PFS)

    Time frame: From date of the first dose of study treatment until the date of first documented disease progression or date of death from any cause, whichever came first, assessed up to 104 weeks

  13. Overall Survival (OS)

    Time frame: From date of the first dose of study treatment until the date of death from any cause, assessed up to 150 weeks

07

Study locations

3 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2020 to primary completion in Dec 2023, 45 months.

Of 163 industry-sponsored phase 1 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 70. This study's 45 months is close to that.

Counting every sponsor, half of 286 studies reached it within 55 months; a quarter within 38 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2020
First posted
Mar 31, 2020
StartActual
Feb 25, 2020
Primary completionActual
Dec 13, 2023
CompletionEst.
Mar 2028
Last update
Jul 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04328844
Lead sponsor
iOnctura
Responsible party
Sponsor
First posted
Mar 31, 2020
Start date
Feb 25, 2020
Primary completion
Dec 13, 2023
Completion
Mar 2028 (estimated)
Last update
Jul 8, 2026

Study contacts

Michael Lahn
study director · iOnctura

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Roginolisib

Start the discussion